Arcus Biosciences (NYSE:RCUS) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsBob Goeltz - CFOHolli Kolkey - VP of Corporate AffairsJen Scott - Executive DirectorJonathan Miller - Managing DirectorJuan Jaen - President and Co-FounderLi Watsek - DirectorRichard Marcus - CMOSalim Syed - Managing DirectorTerry Rosen - CEOYigal Nochomovitz - Director, Biotech Equity ResearchConference Call ParticipantsEmily Bodnar - Biotech Equity Research AnalystNone - AnalystNone - AnalystNone - Analys ...

Core Viewpoint - PAG has achieved significant returns from its investment in Boryu Biotech, marking a successful exit in the Chinese private equity market with a transaction valued at approximately $6.8 billion, the largest of its kind in history [5][6][19]. Investment Performance - PAG's investment in Boryu Biotech has yielded around 3 billion yuan in returns over approximately 39 months, with the firm holding a 44.62% stake valued at over 6 billion yuan prior to the company's IPO [6][21][22]. - The investment strategy included acquiring shares from the parent company, Haizheng Pharmaceutical, and additional funding rounds, leading to a total investment exceeding 4.1 billion yuan [10][19]. Company Growth and Development - Boryu Biotech was established as a strategic response to Haizheng Pharmaceutical's restructuring efforts in 2019, focusing on monoclonal antibody drugs and securing PAG as a key investor [10][11]. - The company has rapidly expanded its product pipeline in immunotherapy, achieving over 1 billion yuan in profit within nine months and projecting revenues to grow from approximately 1.257 billion yuan in 2023 to 1.623 billion yuan in 2024 [13][16]. Market Position and Future Prospects - Boryu Biotech has established itself as a leading player in the immunotherapy sector, with a strong sales and marketing team covering over 4,000 hospitals and 2,000 retail pharmacies in China [15]. - The company has a robust patent portfolio with 43 granted patents and 63 pending applications, enhancing its competitive edge in the market [15]. - Following its IPO, Boryu Biotech is expected to raise additional funds for operations and product development, further solidifying its market position [16][23].

Core Viewpoint - Kewang Pharmaceutical Group is advancing towards becoming the "first MCE (myeloid cell connector) stock" with its innovative immunotherapy pipeline and differentiated target layout in the fields of oncology and autoimmune diseases, showcasing its long-standing source of innovation as it progresses towards capitalization [1][8] Group 1: Company Overview - Kewang Pharmaceutical, established in 2017, is a research-driven clinical-stage biopharmaceutical company focusing on innovative immunotherapy [1] - The company is uniquely positioned in the MCE track, differentiating itself from competitors who primarily focus on TCE therapies in hematological malignancies [3] Group 2: Technology and Innovation - The BiME (bispecific myeloid cell connector) platform is a core competitive asset, demonstrating cross-indication potential in both oncology and autoimmune diseases [4] - BiME's dual-targeting mechanism enhances macrophage phagocytosis of tumor cells while activating CD8 T cell immune responses, showing superior safety and efficacy compared to T cell activation therapies like TCE and CAR-T [4] Group 3: Clinical Development - Kewang has developed three clinical-stage products in oncology, including ES014, the world's first CD39/TGFβ bispecific antibody, which has shown promising safety and efficacy in treating various solid tumors [5] - ES102, a leading hexavalent OX40 agonist, is in advanced clinical stages and shows significant efficacy in combination with PD-1 antibodies for non-small cell lung cancer and head and neck squamous cell carcinoma [6] Group 4: Autoimmune Disease Pipeline - The company is expanding its pipeline in autoimmune diseases with products like ES302 and ES304, which offer innovative treatment mechanisms for conditions like IBD [7] - These products aim to improve treatment convenience and efficacy while minimizing systemic toxicity [7] Group 5: Financial and Strategic Position - Kewang has raised over $250 million in funding from prominent investors, achieving a valuation of nearly $600 million after its Series C financing [7] - The leadership team comprises experienced professionals with over 25 years in the biopharmaceutical industry, enhancing the company's strategic and operational capabilities [7] Group 6: Future Outlook - With its innovative research and strategic partnerships, including a significant collaboration with Astellas worth over $1.7 billion, Kewang is positioned to capture a significant share of the next-generation immunotherapy market [4][8] - The company aims to deliver breakthrough treatment options for global patients, reinforcing its commitment to long-term value creation in the biopharmaceutical sector [8]

Core Viewpoint - Rapt Therapeutics is making headlines due to its acquisition by GSK, which values the deal at approximately $2.2 billion, despite a recent downgrade in its stock rating from Guggenheim [1][2]. Group 1: Acquisition Details - GSK is acquiring Rapt Therapeutics for $58.00 per share, which represents a significant premium and values the total deal at around $2.2 billion [1][2]. - The acquisition involves an upfront investment of $1.9 billion net of cash acquired, allowing GSK to access RAPT's late-stage food allergy treatment, ozureprubart [2]. Group 2: Product Information - Ozureprubart is a long-acting anti-IgE monoclonal antibody currently in phase 2b clinical development, aimed at providing prophylactic protection against food allergens [2]. - This innovative drug targets IgE, a validated target in severe food allergies, and promises a more convenient treatment option compared to existing therapies that require frequent injections [2]. Group 3: Market Reaction and Legal Investigation - Following the acquisition announcement, RAPT's stock surged by 64%, reaching a new 52-week high of $57.61, with a market capitalization of approximately $951.3 million [1][3]. - Halper Sadeh LLC is investigating the fairness of the sale to ensure it aligns with the best interests of RAPT shareholders and whether the board of directors has fulfilled its responsibilities [3].

Core Insights - A research team from Lund University in Sweden has developed a "cell recipe library" that significantly advances the field of immune cell reprogramming, enabling large-scale screening of the "recipes" needed to convert ordinary cells into specific immune cells, which could lead to new therapies for cancer and autoimmune diseases [2][3] Group 1: Technology Development - The team has created a technology platform that allows for the rapid testing of thousands of factor combinations to identify those that can drive the transformation of cells into target immune cell types [2] - Over four years, the team constructed a core toolbox containing more than 400 immune-related reprogramming factors, each tagged with a unique DNA barcode [2] Group 2: Application and Future Goals - The platform has already identified six different reprogramming schemes for various immune cells, including natural killer cells, which are crucial in anti-cancer immunity [3] - The future goal is to establish reprogramming schemes for all immune cell types, thereby accelerating the development of new therapies [3] Group 3: Implications for Treatment - This new technology overcomes the inefficiencies of previous methods that relied on trial and error, potentially expanding the treatment options available for patients, especially those for whom existing therapies are ineffective [4] - If the immune cell "recipe library" can be further expanded, it may demonstrate broader therapeutic potential beyond cancer, providing hope for a larger patient population [4]

Summary of Annexon Conference Call Company Overview - **Company**: Annexon - **Industry**: Biotechnology, specifically focusing on immunotherapy for neuroinflammatory diseases - **Mission**: Deliver game-changing immunotherapy for patients suffering from devastating neuroinflammatory diseases [2][3] Key Programs and Market Opportunities ANX007 for Geographic Atrophy (GA) - **Market Opportunity**: Addressing a market potential of over $10 billion annually, with the ability to treat more than 10 million patients [3][4] - **Phase 3 Data**: Expected release in the second half of 2026, with a focus on vision preservation in patients with GA [4][22] - **Patient Demographics**: Average age of patients in studies is 79 years, with significant vision loss impacting independence [11] - **Efficacy**: Demonstrated protection of 50%-60% of photoreceptor cells, leading to a 73% reduction in the risk of vision loss over 12 months [15][18][19] - **Safety Profile**: Low incidence of adverse events compared to other therapies, with no significant conversion to wet AMD [25] ANX005 for Guillain-Barré Syndrome (GBS) - **Market Opportunity**: Affects 150,000 people worldwide, with a healthcare cost exceeding $7 billion annually in the U.S. [27][28] - **Efficacy**: 90% of treated patients showed improvement by week one, with significant reductions in inflammatory biomarkers [30][31] - **Patient Outcomes**: Patients returned to walking 31 days sooner and were off ventilators 28 days earlier compared to placebo [32] - **Regulatory Status**: Filed for European approval, with plans to submit to the FDA later in 2026 [34] ANX1502 for Autoimmune Conditions - **Development Status**: First oral small molecule candidate targeting autoimmune conditions, with proof of concept data expected in 2026 [5][35] - **Challenges**: Initial formulation issues related to emesis and food effects have been addressed with enteric-coated formulations [46][48] Competitive Advantage - **Scientific Approach**: Focus on targeting C1q in the classical pathway, differentiating from first-generation therapies targeting downstream pathways [6][24] - **Experienced Leadership**: The team has over 100 years of combined biotech experience, enhancing the company's ability to navigate challenges [9] Regulatory and Commercial Strategy - **Regulatory Designations**: Prime designation in the EU and fast track designation in the U.S. for ANX007 [22][40] - **Market Preparation**: Actively preparing for market entry with effective medical education and pre-commercial activities [5] Conclusion - **Transformational Year**: 2026 is positioned as a pivotal year for Annexon, with significant milestones expected in both GA and GBS programs [34] - **Investment Opportunity**: The company presents a unique value proposition for investors, particularly with its late-stage programs and differentiated therapeutic approaches [9][23]

Core Viewpoint - Zhejiang Borui Biopharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, aiming to provide comprehensive immunotherapy solutions for patients with autoimmune and inflammatory diseases, as well as tumor immunology diseases [1] Group 1: Company Overview - Borui Biopharmaceutical is an integrated biopharmaceutical company focusing on immunotherapy, which aims to address diseases where immune dysregulation plays a critical role [1] - The company ranks first among Chinese pharmaceutical companies in revenue from biopharmaceuticals for autoimmune diseases for two consecutive years starting in 2023, according to Frost & Sullivan [1] Group 2: Product Portfolio - The innovative product lineup includes the first-in-class and best-in-class IL-17A/F inhibitor Beijiele® (Bicizumab), the first and only innovative CD20 monoclonal antibody Anruixi (Zebetomab), and BR2251, a potential first-in-class gout drug with a differentiated mechanism of action [2] - These cornerstone immunology products provide a solid foundation for the company's growth and enable the transformation of treatment models for various autoimmune diseases and oncology indications in China [2] Group 3: Financial Performance - For the fiscal years ending September 30, 2023, 2024, and 2025, the company reported revenues of approximately 1.257 billion yuan, 1.623 billion yuan, and 1.379 billion yuan, respectively [2] - The gross profits for the same periods were approximately 1.033 billion yuan, 1.286 billion yuan, and 1.025 billion yuan, with corresponding gross margins of 82.2%, 79.2%, and 74.4% [2] - The net profits attributable to equity shareholders were approximately 19.05 million yuan, 91.295 million yuan, and 122 million yuan for the respective periods [2]

Company Overview - Zhejiang BoRui Biopharmaceutical Co., Ltd. is a leading integrated biopharmaceutical company in China, focusing on providing comprehensive immunotherapy solutions for patients with autoimmune and inflammatory diseases, as well as tumor immunology diseases [3] - The company has ranked first among Chinese pharmaceutical companies in terms of revenue from biological agents for autoimmune diseases for two consecutive years starting in 2023, according to Frost & Sullivan [3] - BoRui Biopharmaceutical strategically focuses on immunotherapy, utilizing immune science to regulate immune function and address diseases where immune dysregulation plays a critical role [3] Product Portfolio - The innovative product lineup includes the first-in-class IL-17A/F inhibitor Beijiele (Bicizumab), China's first and only innovative CD20 monoclonal antibody Anruixi (Zebetomab), and BR2251, a potential first-in-class gout drug with a differentiated mechanism of action [4] - The company has established one of the most competitive and comprehensive immunological product portfolios in the industry, supported by eight commercialized products and a pipeline of innovative candidates [4] Financial Performance - For the fiscal years ending December 31, 2023, 2024, and the nine months ending September 30, 2025, the company reported revenues of approximately RMB 1.257 billion, RMB 1.623 billion, and RMB 1.379 billion, respectively [5] - The profit attributable to equity shareholders for the same periods was RMB 19.01 million, RMB 91.30 million, and RMB 121.84 million, respectively [6] - The gross profit margins for the fiscal years were 82.2%, 79.2%, and 74.4% [8] Industry Overview - The autoimmune disease market is one of the fastest-growing sectors in the global pharmaceutical market, with a projected compound annual growth rate (CAGR) of 21.9%, expanding from RMB 174 billion in 2020 to RMB 328 billion by 2024, and expected to reach RMB 2,899 billion by 2035 [10] - The market for biological agents in autoimmune diseases is also rapidly expanding, with a CAGR of 42.5%, expected to grow from RMB 42 billion in 2020 to RMB 171 billion by 2024, and projected to reach RMB 2,126 billion by 2035 [10] - The tumor immunology market is anticipated to grow from RMB 148 billion in 2020 to RMB 293 billion by 2024, with a CAGR of 18.5%, and is expected to further expand to RMB 4,954 billion by 2035, driven by the approval of innovative therapies [13] Shareholding Structure - As of December 29, 2025, the company's equity is held by PAG Highlander and Haizheng Pharmaceutical, owning 44.62% and 39.62% of the shares, respectively [21]

Company Overview - Zhejiang Borui Biopharmaceutical Co., Ltd. is a leading integrated biopharmaceutical company in China, focusing on providing comprehensive immunotherapy solutions for patients with autoimmune and inflammatory diseases, as well as tumor immunology diseases [3] - The company has ranked first among Chinese pharmaceutical companies in terms of revenue from biological agents for autoimmune diseases for two consecutive years starting in 2023, according to Frost & Sullivan [3] - Borui Biopharmaceutical strategically focuses on immunotherapy, utilizing immune science to regulate immune function to address diseases where immune dysregulation plays a critical role [3] Product Portfolio - The innovative product portfolio includes leading immunology products such as the first-in-class IL-17A/F inhibitor Beijiele® (Bicizumab), the first and only innovative CD20 monoclonal antibody Anruixi (Zebetumab), and BR2251, a potential first-in-class gout drug with a differentiated mechanism of action [4] - The company has established one of the most competitive and comprehensive immunology product portfolios in the industry, supported by eight commercialized products and an expanding pipeline of innovative candidates [4] Financial Performance - For the fiscal years ending December 31, 2023, 2024, and the nine months ending September 30, 2025, the company reported revenues of approximately RMB 1.257 billion, RMB 1.623 billion, and RMB 1.379 billion, respectively [6] - The profit attributable to equity shareholders for the same periods was RMB 19.01 million, RMB 91.30 million, and RMB 121.84 million [7] - The gross profit margins for the fiscal years were 82.2%, 79.2%, and 74.4% respectively [9] Industry Overview - The autoimmune disease market is one of the fastest-growing sectors in the global pharmaceutical market, with a projected market size in China growing from RMB 174 billion in 2020 to RMB 328 billion in 2024, and expected to reach RMB 2,899 billion by 2035, with a compound annual growth rate (CAGR) of 21.9% [11] - The market for biological agents is also expanding rapidly, with a projected growth from RMB 42 billion in 2020 to RMB 171 billion in 2024, and expected to reach RMB 2,126 billion by 2035, with a CAGR of 25.7% [11] - The tumor immunology market is expected to grow from RMB 148 billion in 2020 to RMB 293 billion in 2024, with a CAGR of 18.5%, and further expand to RMB 4,954 billion by 2035, with a CAGR of 29.3% from 2024 to 2035 [15] Shareholding Structure - As of December 29, 2025, the company's equity is held by PAG Highlander and Haizheng Pharmaceutical, owning 44.62% and 39.62% respectively [24]

Core Viewpoint - The study reveals a novel regulatory axis involving GPX4 and ZP3 receptors that impairs antitumor immunity during ferroptosis, suggesting new therapeutic targets for cancer immunotherapy, especially for patients unresponsive to existing treatments [2][3][16]. Group 1: Mechanism of Action - The research identifies that during ferroptosis, cancer cells release GPX4 protein, which binds to ZP3 receptors on dendritic cells, activating a signaling cascade that inhibits glycolysis and impairs dendritic cell maturation and activation, leading to T cell activation defects [3][6][14]. - Disruption of the GPX4-ZP3 interaction can restore dendritic cell metabolic activity and enhance antitumor immunity, indicating a potential therapeutic strategy [3][16]. Group 2: Clinical Implications - Clinical data show that higher serum levels of GPX4 correlate with poorer treatment outcomes, and elevated ZP3 expression is associated with unfavorable prognosis across various solid tumors [16][18]. - In preclinical models, blocking the GPX4-ZP3 interaction significantly enhances the efficacy of chemotherapy, immunotherapy, and radiotherapy, providing a new approach to overcoming tumor resistance [16][19]. Group 3: Future Directions - The findings open avenues for personalized cancer immunotherapy by targeting the GPX4-ZP3 pathway, potentially benefiting patients who do not respond to current immunotherapies [18][19]. - Ongoing research aims to translate these discoveries into clinical applications, with the possibility of using GPX4 and ZP3 levels as biomarkers for tailored treatment strategies [19][20].